Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
6 p, 754.7 KB Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer : a post hoc analysis of the MOSAIC trial / Auclin, Edouard (Bourgogne Franche-Comté University, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France) ; André, Thierry (Oncology Multidisciplinary Research Group (GERCOR)) ; Taieb, Julien (UMR-S 1147, INSERM) ; Banzi, Maria (Unit of Medical Oncology, Clinical Cancer Center, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy) ; Van Laethem, Jean-Luc (Université Libre de Bruxelles. Department of Gastroenterology and Digestive diseases, Hopital Erasme) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Hickish, Tamas (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ; de Gramont, Aimery (Institut Hospitalier Franco-Britannique. Department of Oncology) ; Vernerey, Dewi (Oncology Multidisciplinary Research Group (GERCOR)) ; Universitat Autònoma de Barcelona
Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2. 35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant treatment. [...]
2019 - 10.1038/s41416-019-0521-7
British Journal of Cancer, Vol. 121 (july 2019) , p. 312-317  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.